Epigenetic approaches in stem cell transplantation

Clinical Epigenetics

Table 2 Epigenetic agents prior to HSCT (allogeneic haematopoietic transplantation)

Author	n	Agent	Disease	Remission	Outcome after HSCT	[median] Follow-up (months)	Reference
Lübbert 2006	10	Dec	AML/MDS	40% CR, 10% PR	33% relapse, 33% alive	26/10/1	(Lubbert et al. 2006)
De Padua 2007	12	Dec	MDS	33% CR, 50% PR	17% relapse, 75% alive	11.5	(De Padua Silva et al. 2007)
McCarty 2008	25	5-Aza	AML/MDS	52% ORR		12	(McCarty et al. 2008)
de Lima 2003	23	Dec	12× AML, 1xCMML, 1× ALL, 9× CML	91% CR	39% relapse, 26% alive	39	(de Lima et al. 2003)
Giralt 1997	4	Dec	3× CML, 1× AMML	2× CR	3× alive	6	(Giralt et al. 1997)

Dec decitabine, 5-Aza 5-azacytidine, AML acute myeloid leukaemia, MDS myelodysplasia, CMML chronic myelomonocytic leukaemia, CML chronic myeloid leukaemia, ALL acute lymphoblastic leukaemia, AMML acute myelomonocytic leukaemia, CR complete remission, PR partial remission, ORR overall response rate

ISSN: 1868-7083